Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy
Background. New pathogenetic treatment options, such as gene therapy, are now used to treat previously uncurable diseases. However, price of such treatment is high, especially in the case of orphan diseases, where costs may many-fold exceed the prices for other types of medication. This raises a que...
Збережено в:
| Автори: | , , |
|---|---|
| Формат: | Artigo |
| Мова: | Russo |
| Опубліковано: |
IRBIS LLC
2022-01-01
|
| Серія: | Фармакоэкономика |
| Предмети: | |
| Онлайн доступ: | https://www.pharmacoeconomics.ru/jour/article/view/623 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|